Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
    • Publication Information:
      Publication: Jan. 2011- : Oxford : Oxford University Press
      Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press
    • Subject Terms:
      Antibodies, Fungal/*blood ; Candida/*immunology ; Candidiasis/*prevention & control ; Fungal Proteins/*immunology ; Fungal Vaccines/*immunology; Candidiasis/immunology ; Cytokines/metabolism ; Enzyme-Linked Immunosorbent Assay ; Humans ; Immunodominant Epitopes ; Immunoglobulin A/blood ; Immunoglobulin E/blood ; Immunoglobulin G/blood
    • Abstract:
      We determined reactivity of human blood to a vaccine based on the recombinant N-terminus of candidal Als3p (rAls3p-N) in preparation for future clinical trials. Healthy donor plasma had high immunoglobulin G titers (median, 1:51,200) and lower immunoglobulin A (median, 1:3,200) and immunoglobulin E (median, 1:128) titers to rAls3p-N by enzyme-linked immunosorbent assay. rAls3p-N stimulated interferon gamma (IFN-gamma) and interleukin (IL)-17, but not IL-4, from donor lymphocytes by enzyme-linked immunosorbent spot assay and IL-12 p70, IFN-gamma, IL-17, and IL-10 by cytometric bead array. Donors reacted to diverse immunodominant epitopes. Thus, facile humoral and cellular assays can monitor immune responses to the rAls3p-N vaccine in planned clinical trials.
    • References:
      Clin Vaccine Immunol. 2008 Mar;15(3):582-4. (PMID: 18184821)
      Pediatrics. 1998 Jul;102(1 Pt 2):252-4. (PMID: 9651448)
      Semin Respir Crit Care Med. 2009 Apr;30(2):189-209. (PMID: 19296419)
      PLoS Pathog. 2009 Dec;5(12):e1000703. (PMID: 20041174)
      Curr Genet. 1998 Jun;33(6):451-9. (PMID: 9644209)
      Clin Infect Dis. 2004 Aug 1;39(3):309-17. (PMID: 15306996)
      Clin Exp Immunol. 2002 Feb;127(2):344-53. (PMID: 11876760)
      J Infect Dis. 2008 Apr 1;197(7):967-71. (PMID: 18419471)
      FEMS Immunol Med Microbiol. 2009 Apr;55(3):293-5. (PMID: 19159425)
      J Infect Dis. 1988 Nov;158(5):948-55. (PMID: 3183428)
      Infect Immun. 2008 Oct;76(10):4574-80. (PMID: 18644876)
      Clin Infect Dis. 2008 Aug 1;47(3):401-9. (PMID: 18558875)
      N Engl J Med. 1990 Nov 15;323(20):1381-7. (PMID: 2233904)
      Clin Infect Dis. 1993 Jul;17(1):66-73. (PMID: 8353248)
      Med Mycol. 2007 Jun;45(4):321-46. (PMID: 17510856)
    • Grant Information:
      R01 AI063382 United States AI NIAID NIH HHS; R01 AI072052 United States AI NIAID NIH HHS; R01 AI072052-03 United States AI NIAID NIH HHS; AI063382 United States AI NIAID NIH HHS
    • Accession Number:
      0 (Antibodies, Fungal)
      0 (Cytokines)
      0 (Fungal Proteins)
      0 (Fungal Vaccines)
      0 (Immunodominant Epitopes)
      0 (Immunoglobulin A)
      0 (Immunoglobulin G)
      37341-29-0 (Immunoglobulin E)
    • Publication Date:
      Date Created: 20091231 Date Completed: 20100127 Latest Revision: 20211020
    • Publication Date:
      20231215
    • Accession Number:
      PMC2812804
    • Accession Number:
      10.1086/649901
    • Accession Number:
      20039802